An article in the New England Journal of Medicine (Volume 394, Number 11, Pages 1123-1124, March 12/19, 2026) discusses the COBRRA trial, which addresses the safety of venous thromboembolism prevention. The study ends the uncertainty in choosing between different prothrombotic strategies. The main findings focus on comparing the effectiveness and risks of individual approaches. The trial provides evidence of a reduced risk of bleeding and thromboembolism in patients. The results show specific statistics on the incidence of complications in patient groups. The COBRRA trial brings clearer recommendations for clinical practice.